GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (LSE:DDDD) » Definitions » Net Income From Continuing Operations

4d pharma (LSE:DDDD) Net Income From Continuing Operations : £-53.96 Mil (TTM As of Dec. 2021)


View and export this data going back to 2014. Start your Free Trial

What is 4d pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. 4d pharma's net income from continuing operations for the six months ended in Dec. 2021 was £-35.95 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2021 was £-53.96 Mil.

4d pharma Net Income From Continuing Operations Historical Data

The historical data trend for 4d pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Net Income From Continuing Operations Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Income From Continuing Operations
Get a 7-Day Free Trial -20.45 -25.69 -23.13 -25.96 -53.96

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.14 -13.73 -12.24 -18.01 -35.95

4d pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-53.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4d pharma (LSE:DDDD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (LSE:DDDD) » Definitions » Net Income From Continuing Operations
Comparable Companies
LSE:4BB LSE:C4XD LSE:ONC LSE:SNG LSE:APTA LSE:OKYO LSE:SBTX LSE:OBI LSE:FUM LSE:DEST OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
Website
https://www.4dpharmaplc.com
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (LSE:DDDD) Headlines

No Headlines